EmitBio Inc. is excited to announce its participation in the World Congress on Infectious Diseases, scheduled to take place from October 23 to 25, 2023 in Boston, Massachusetts.
|
Presentation Covers Results From the Company's Phase II Dose Finding COVID-19 Clinical Trial MORRISVILLE, N.C., Aug. 8, 2023 /PRNewswire/ -- EmitBio Inc. is excited to announce its participation in the World Congress on Infectious Diseases, scheduled to take place from October 23 to 25, 2023 in Boston, Massachusetts. EmitBio has been invited as a distinguished speaker at this premier event and will present findings from the Phase II clinical study of its RD-X19 treatment device* in individuals with mild-to-moderate COVID-19.
Dr. Jacob Kocher, Director of Virology for EmitBio, will present the findings of EmitBio's sham-controlled dose-finding study of 216 subjects conducted at multiple clinical sites across the United States. In this study, EmitBio evaluated the safety and efficacy of its novel light-based therapy RD-X19, an investigational handheld, self-administered medical device. The RD-X19 delivers precise doses of high energy blue light to the posterior oropharynx and surrounding tissues, providing a potential new outpatient treatment option for COVID-19. In the study, the device was well-tolerated and showed promising results in improving symptomatic relief, particularly in subjects aged 40 years and above with mild COVID-19. Additionally, EmitBio's research showed the light-based therapy achieved these antiviral effects without disrupting the oral microbiome, a crucial finding further illustrating the device's safety and potential for clinical use. "It is an honor to present our findings to the global community of experts at the World Congress on Infectious Diseases," said Dr. Kocher. "COVID-19 remains a significant disease on the world stage as the virus continues to mutate and present new challenges to public health measures. Our mechanism of action works on both the virus and the host to provide synergistic effects and an overall antiviral environment in the upper respiratory tract not afforded by currently available oral antivirals. This unique combination has the added benefit of making this technology variant agnostic and therefore is an important finding for treatment of current and future coronavirus threats." EmitBio's technology utilizes precise, monochromatic wavelengths of visible light to combat infectious diseases, particularly diseases stemming from respiratory viral infections caused by coronaviruses. EmitBio's studies have shown that certain wavelengths and doses of visible light exhibit potent antiviral effects by inactivating cell-free SARS-CoV-2 and reducing viral titers in productive infection models of the human airway. About COVID-19 About The World Congress on Infectious Diseases About EmitBio Inc. * The EmitBio RD-X19 device is investigational and not currently available for sale. Media and Investor Contact:
SOURCE EmitBio Inc. |
View original content to download multimedia:
